Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.77 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.77 |
| ▸ | CYP4Z1 | Q86W10 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.50 |
| ▸ | CYP4F11 | Q9HBI6 | 1/20 | 0.49 |
| ▸ | CYP4F12 | Q9HCS2 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.47 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL68902 | 0.94 | CYP4F2 (0.85) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL10289874 | 0.89 | CYP4F2 (0.62) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL879130 | 0.89 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL10206072 | 0.89 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL11437256 | 0.89 | CYP4F2 (0.77) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL24988200 | 0.87 | CYP4F2 (0.60) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL14570534 | 0.87 | CYP4Z1 (0.62) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL5543917 | 0.87 | CYP4F2 (0.74) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL4889211 | 0.87 | CYP4F2 (0.80) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA | |
| SCHEMBL22098222 | 0.87 | CYP4F2 (1.00) | CYP4F2CYP4A11CYP4Z1L3MBTL1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) | 2025-08-26 | — | — | US | disclosed |
| CN-113461559-B | Compound, compound product, preparation method and application | 中国人民解放军军事科学院军事医学研究院 | 2023-08-08 | — | — | CN | disclosed |
| US-20220298097-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND | NANJING CHENGZHI CLEAN ENERGY CO. LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| CN-111087306-B | Method for preparing organic carboxylic ester by aryl bidentate phosphine ligand combined catalysis | 南京诚志清洁能源有限公司 | 2021-08-03 | — | — | CN | disclosed |
| WO-2021129138-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY MEANS OF COMBINATORIAL CATALYSIS WITH ARYL BIDENTATE PHOSPHINE LIGAND | 南京诚志清洁能源有限公司 | 2021-07-01 | — | — | WO | disclosed |
| WO-2021129138-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY MEANS OF COMBINATORIAL CATALYSIS WITH ARYL BIDENTATE PHOSPHINE LIGAND | 南京诚志清洁能源有限公司 | 2021-07-01 | — | — | WO | disclosed |
| CN-111087306-A | Method for preparing organic carboxylic ester by aryl bidentate phosphine ligand combined catalysis | 南京诚志清洁能源有限公司 | 2020-05-01 | — | — | CN | disclosed |
| CN-108419435-A | Compound and epigenetics for treating cancer | 新加坡科技研究局 | 2018-08-17 | — | — | CN | disclosed |
| CN-107548397-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| CN-107548396-A | Kv1.3 inhibitors and medical uses thereof | 4SC股份公司 | 2018-01-05 | — | — | CN | disclosed |
| WO-2006004742-A2 | α, β-UNSATURATED ESTERS AND ACIDS BY STEREOSELECTIVE DEHYDRATION | JANSSEN PHARAMCEUTICA N.V. (BE) | 2006-01-12 | — | — | WO | disclosed |
| EP-1564200-A1 | Ketone compounds and compositions for cholesterol management and related uses | Esperion Therapeutics Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| EP-1551826-A1 | HYDANTOINE DERIVATIVES AND THEIR USE AS TACE INHIBITORS | Astrazeneca AB (SE) | 2005-07-13 | — | — | EP | disclosed |
| EP-0786691-B1 | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity | EASTMAN KODAK CO (US) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004024721-A1 | HYDANTOIN DERIVATIVES UND DEREN VERWENDUNG ALS TACE INHIBITOREN | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2002030860-A9 | KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES | ESPERION THERAPEUTICS INC (US) | 2003-02-20 | — | — | WO | disclosed |
| US-5747236-A | FRAGMENTABLE ELECTRON DONOR | EASTMAN KODAK COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0786691-A1 | Silver halide light sensitive emulsion layer having enhanced photographic sensitivity | EASTMAN KODAK COMPANY (US) | 1997-07-30 | — | — | EP | disclosed |
| US-5220060-A | Reacting ester with carbon monoxide in liquid phase with catalyst system of palladium compound, iodide promoter, proton donor | CHEVRON RESEARCH AND TECHNOLOGY COMPANY (US) | 1993-06-15 | — | — | US | disclosed |
| US-5008451-A | Producing carboxylic anhydrides by reacting a carboxylic ester with carbon monoxide using a phodium catalyst, iodide promoter, proton donor and anhydrous conditions | CHEVRON RESEARCH COMPANY (US) | 1991-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220298097-A1 | METHOD FOR PREPARING ORGANIC CARBOXYLIC ESTER BY USING COMBINED CATALYST OF ARYL BIDENTATE PHOSPHINE LIGAND | POF1B, ADH1C, OSBP | CYP4F2 57/4885CYP4A11 53/4885CYP4Z1 952/4885 |
| US-12398089-B2 | Method for preparing organic carboxylic ester by using combined catalyst of aryl bidentate phosphine ligand | POF1B, ADH1C, OSBP | CYP4F2 57/4885CYP4A11 53/4885CYP4Z1 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.